Novartis delivers excellent performance in third quarter
- Details
- Category: Novartis
Net sales rose 13% (+16% cc) to USD 12.6 billion with strong contributions from all businesses. Currency movements depressed the result by 3 percentage points. Rapid growth of recently launched products across the Group generated USD 2.3 billion in sales, representing 20%* of total sales.
US FDA Approves Pradaxa® (dabigatran etexilate)
- Details
- Category: Boehringer Ingelheim
The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate),(1) Boehringer Ingelheim's novel, oral direct thrombin inhibitor(2) for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.
Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines.
Genzyme Reports Financial Results for the Third Quarter of 2010
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter.
Genzyme Announces Results of Phase 3 Trial of Clolar
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced results from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
Sanofi-aventis Establishes Research Collaboration with Harvard University
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard University and sanofi-aventis.
Biocon and Pfizer Enter Into Global Commercialization Agreement
- Details
- Category: Pfizer
Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro.
More Pharma News ...
- Roche Group posts solid sales growth in first nine months
- GSK outlines approach to delivering advances in the treatment of rare diseases
- Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis
- 21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment
- GSK increases support for WHO strategy to improve children's health
- Merck KGaA to Introduce RebiDose, the Rebif Single Use Pre-filled Pen for Treatment of Multiple Sclerosis
- Results from a national survey of Alzheimer's Disease